ABSTRACT
Background Epigenetic alterations upon microbial challenge have been described as both a defence strategy and a result of pathogenic manipulation. While most COVID-19 studies focus on inflammatory and immune-mediated responses, little is known about epigenetic modifications in response to SARS-CoV-2 infection.
Methods Epigenome-wide DNA methylation patterns from COVID-19 convalescents were compared to uninfected controls from before and after the pandemic. Peripheral blood mononuclear cell (PBMC) DNA was extracted from uninfected controls, COVID-19 convalescents and symptom-free individuals with SARS-CoV-2-specific T cell-responses, as well as from PBMCs stimulated in vitro with SARS-CoV-2. Subsequently, the Illumina MethylationEPIC 850K array was performed, and statistical/bioinformatic analyses comprised differential DNA methylation, pathway over-representation and module identification analyses.
Results Differential DNA methylation patterns distinguished COVID-19 convalescents from uninfected controls, with similar results in an experimental SARS-CoV-2 infection model. A SARS-CoV-2-induced module was identified in vivo, comprising 66 genes of which six (TP53, INS, HSPA4, SP1, ESR1 and FAS) were present in corresponding in vitro analyses. Over-representation analyses revealed involvement in Wnt, muscarinic acetylcholine receptor signalling and gonadotropin-releasing hormone receptor pathways. Furthermore, numerous differentially methylated and network genes from both settings interacted with the SARS-CoV-2 interactome.
Conclusions Altered DNA methylation patterns of COVID-19 convalescents suggest recovery from mild-to-moderate SARS-CoV-2 infection leaves longstanding epigenetic traces. As in vitro SARS-CoV-2 infection corroborated in vivo exposure results, this indicates DNA methylation is involved in immune cell responses to challenge with this virus. Future studies should determine whether this reflects host-induced protective antiviral defence or targeted viral hijacking to evade host defence.
Competing Interest Statement
M.L., S.Sa. and J.D. have prepared and filed a patent based on the findings from the present study. None of the remaining authors declare any competing interests.
Funding Statement
This work was supported by the Swedish Heart and Lung Foundation under grants 20200319, 20200067 and 20210067 (M.L); the Swedish Research Council under grant Covid-19/biobank 210202#1 (A.R.) and the Open Medicine foundation under grant OMF190626 (A.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Regional Ethics Committee for Human Research in Linkoeping (Dnr. 2019-0618)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared first authorship
Johanna Huoman @HuomanJohanna, Shumaila Sayyab @shum_sayyab, Lovisa Karlsson @LovisaElisabet, Jyotirmoy Das @Jyotirmoy21, Maria Lerm @LermLab
The introduction has been modified, the results compacted and the discussion slimmed.
Data Availability
The datasets used and/or analysed in the presented work will be available upon publication on GeneExpression Omnibus, due to a pending patent application. The datasets comprise filtered and preprocessed DNA methylation data from deidentified individual samples in the study. The dataset will until publication be available using a secure token, provided by the authors upon request. Please, refer to GEO-ID: GSE178962 for further information on the data set. Utilised scripts for performing the described statistical analyses within the paper, as well as for creating graphs, will be available on the following GitHub account upon publication (https://github.com/Lerm-Lab/Covid19).
